Castellano | Euskara | Français | English
DAR No 6. Tafluprost (Saflutan®) for elevated intraocular pressure in open-angle glaucoma and ocular hypertension
Share it
A new prostaglandin analogue with no advantages
- Tafluprost is indicated in the reduction of elevated intraocular pressure in patients with open-angle glaucoma and ocular hypertension, both in monotherapy in cases of intolerance to preservatives, or as adjunctive therapy with beta-blockers.
- Data on the efficacy of tafluprost compared to other prostaglandin analogues originate from a single clinical trial in which non-inferiority was not shown when compared to latanoprost.
- It presents a similar profile to other prostaglandin analogues regarding adverse reactions. The most frequent adverse effect is ocular and conjunctival hyperaemia.
- Despite being the first prostaglandin analogue free of preservatives, it has not shown better tolerance compared to the other analogues containing preservatives.
